Jean-Simon Diallo

Expression and nuclear localization of ErbB3 in prostate cancer.

An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.

Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.

NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells.

Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer.

NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.

Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines.

Intelligent design: combination therapy with oncolytic viruses.

Synergistic interaction between oncolytic viruses augments tumor killing.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

A novel method of cell embedding for tissue microarrays.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers.